PT - JOURNAL ARTICLE AU - Ranzani, Otavio T. AU - Hitchings, Matt D.T. AU - de Melo, Rosana Leite AU - de França, Giovanny V. A. AU - Fernandes, Cássia de Fátima R. AU - Lind, Margaret L AU - Scaramuzzini Torres, Mario Sergio AU - Tsuha, Daniel Henrique AU - David, Leticia C. S. AU - Said, Rodrigo F. C. AU - Almiron, Maria AU - de Oliveira, Roberto D. AU - Cummings, Derek A.T. AU - Dean, Natalie E AU - Andrews, Jason R. AU - Ko, Albert I. AU - Croda, Julio TI - Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant AID - 10.1101/2022.03.30.22273193 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.30.22273193 4099 - http://medrxiv.org/content/early/2022/04/01/2022.03.30.22273193.short 4100 - http://medrxiv.org/content/early/2022/04/01/2022.03.30.22273193.full AB - Background Large outbreaks of the SARS-CoV-2 Omicron (B.1.1.529) variant have occurred in countries with high coverage of inactivated Covid-19 vaccines, raising urgent questions about effectiveness of these vaccines against disease and hospitalization with Omicron.Methods We conducted a nationwide, test-negative, case-control study of adults who were tested for SARS-CoV-2 infection. We evaluated vaccine effectiveness against symptomatic Covid-19 and severe Covid-19 (hospital admission or deaths) for the primary series of CoronaVac and homologous and heterologous (BNT162b2) booster doses.Findings Between September 6, 2021, and March 10, 2022, a total of 1,339,986 cases were matched to 1,339,986 test-negative controls. In the period of Omicron predominance, vaccine effectiveness ≥180 days after the second CoronaVac dose was 8·1% (95% CI, 7·0 to 9·1) and 57·0% (95% CI, 53·5 to 60·2) against symptomatic and severe Covid-19, respectively. Vaccine effectiveness against symptomatic disease was 15·0% (95% CI, 12·0 to 18·0) and 56·8% (95% CI, 56·3 to 57·4) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, vaccine effectiveness against severe Covid-19 was 71·3% (95% CI, 60·3 to 79·2) and 85·5% (95% CI, 83·3 to 87·0) after receiving a homologous and heterologous booster, respectively. Whereas waning of vaccine effectiveness against symptomatic Covid-19 was observed ≥90 days after a homologous and heterologous booster, waning against severe Covid-19 was only observed after a homologous booster.Interpretation A homologous CoronaVac booster dose provided limited additional protection, while a BNT162b2 booster dose afforded sustained protection against severe disease for at least three months.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnnAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committee for research of Federal University of Mato Grosso do Sul (CAAE: 43289221.5.0000.0021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing: Deidentified databases as well as the R codes will be deposited in the repository https://github.com/juliocroda/VebraCOVID-19 https://github.com/juliocroda/VebraCOVID-19